ELYXYB Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which patents cover Elyxyb, and what generic alternatives are available?
Elyxyb is a drug marketed by Bdsi and is included in one NDA. There are six patents protecting this drug.
This drug has twenty-five patent family members in twelve countries.
The generic ingredient in ELYXYB is celecoxib. There are twenty-six drug master file entries for this compound. Fifty-nine suppliers are listed for this compound. Additional details are available on the celecoxib profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Elyxyb
A generic version of ELYXYB was approved as celecoxib by MYLAN on May 30th, 2014.
Summary for ELYXYB
International Patents: | 25 |
US Patents: | 6 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 165 |
Patent Applications: | 5,179 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ELYXYB |
What excipients (inactive ingredients) are in ELYXYB? | ELYXYB excipients list |
DailyMed Link: | ELYXYB at DailyMed |


Pharmacology for ELYXYB
Drug Class | Nonsteroidal Anti-inflammatory Drug |
Mechanism of Action | Cyclooxygenase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for ELYXYB
US Patents and Regulatory Information for ELYXYB
ELYXYB is protected by six US patents and one FDA Regulatory Exclusivity.
Patents protecting ELYXYB
Oral composition of celecoxib for treatment of pain
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS
Oral composition of celecoxib for treatment of pain
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS
Oral composition of celecoxib for treatment of pain
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS
Oral composition of celecoxib for treatment of pain
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS
Oral composition of celecoxib for treatment of pain
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS
Oral composition of celecoxib for treatment of pain
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS
FDA Regulatory Exclusivity protecting ELYXYB
NEW PRODUCT
Exclusivity Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bdsi | ELYXYB | celecoxib | SOLUTION;ORAL | 212157-001 | May 5, 2020 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Bdsi | ELYXYB | celecoxib | SOLUTION;ORAL | 212157-001 | May 5, 2020 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bdsi | ELYXYB | celecoxib | SOLUTION;ORAL | 212157-001 | May 5, 2020 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Bdsi | ELYXYB | celecoxib | SOLUTION;ORAL | 212157-001 | May 5, 2020 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Bdsi | ELYXYB | celecoxib | SOLUTION;ORAL | 212157-001 | May 5, 2020 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for ELYXYB
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Pfizer Limited | Onsenal | celecoxib | EMEA/H/C/000466 Onsenal is indicated for the reduction of the number of adenomatous intestinal polyps in familial adenomatous polyposis (FAP), as an adjunct to surgery and further endoscopic surveillance (see section 4.4).The effect of Onsenal-induced reduction of polyp burden on the risk of intestinal cancer has not been demonstrated (see sections 4.4 and 5.1) |
Withdrawn | no | no | no | 2003-10-17 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for ELYXYB
See the table below for patents covering ELYXYB around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
China | 114469858 | 用于治疗疼痛的塞来昔布口服组合物 (Oral composition of celecoxib for treating pain) | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2017208069 | ⤷ Try a Trial | |
Canada | 2987272 | COMPOSITION ORALE DE CELECOXIB POUR LE TRAITEMENT DE LA DOULEUR (ORAL COMPOSITION OF CELECOXIB FOR TREATMENT OF PAIN) | ⤷ Try a Trial |
Japan | 2018516266 | 疼痛治療のためのセレコキシブの経口用組成物 | ⤷ Try a Trial |
European Patent Office | 3463340 | COMPOSITION DE CÉLÉCOXIB À USAGE ORAL POUR LE TRAITEMENT DE LA DOULEUR (ORAL COMPOSITION OF CELECOXIB FOR TREATMENT OF PAIN) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ELYXYB
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0731795 | 10075033 | Germany | ⤷ Try a Trial | PRODUCT NAME: CELECOXIB; NAT. REGISTRATION NO/DATE: 48802.00.00 20000518; FIRST REGISTRATION: SE 14838 19991203 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |